BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cemdisiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cemdisiran\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06479863-5168@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Cemdisiran: Phase 1 readout est. (NCT06479863)
DESCRIPTION:Cemdisiran\, phase 1.\nStudy: Efficacy and Safety of Pozelimab 
 and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Bod
 y Myositis\nEstimated primary completion: 30 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06479863
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06541704-5168@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT06541704)
DESCRIPTION:Cemdisiran\, phase 3\, Age-Related Macular Degeneration.\nStudy
 : A Study Investigating Subcutaneously Administered Pozelimab in Combinati
 on With Cemdisiran or Cemdisiran Alone in Adult Participants With Geograph
 ic Atrophy\nEstimated primary completion: 31 July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06541704
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744921-5168@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT05744921)
DESCRIPTION:Cemdisiran\, phase 3.\nStudy: A Study in Adult Patients With Pa
 roxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Tre
 atment With Pozelimab + Cemdisiran Combination Therapy is and How Well it 
 Works\nEstimated primary completion: 10 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05744921
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154745-5168@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20300118
DTEND;VALUE=DATE:20300119
SUMMARY:Cemdisiran: Phase 3 readout est. (NCT07154745)
DESCRIPTION:Cemdisiran\, phase 3.\nStudy: A Study to Evaluate How Pozelimab
  + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal 
 Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Effi
 ciently\nEstimated primary completion: 18 January 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemdisiran#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07154745
URL:https://assetmemo.bio/drug/cemdisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
